Abstract
For effective tumour imaging by magnetic resonance imaging (MRI) there is a clear need to develop organ, tissue and cell specific contrast agents that can selectively bind to tumour biomarkers. The versatility of a range of bioconjugation techniques and facile coupling chemistries has facilitated the synthesis of MRI contrast agents bearing tumour targeting moieties that comprise small molecule affinity ligands, peptides, antibodies and even proteins. The aim of this review is to describe the development and implementation of tumour targeted T1 MRI contrast agents, with an emphasis on the chemistry used to modify pre-existing clinical MRI contrast agents for targeted tumour imaging.
Keywords: MRI, MRI contrast agents, Gadolinium, Cancer, Tumour, Tumour targeting, T1 contrast agents, Nanoparticles, Nanomedicine, Paramagnetic contrast agents
Current Topics in Medicinal Chemistry
Title: Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Volume: 10 Issue: 12
Author(s): Nazila Kamaly, Andrew D. Miller and Jimmy D. Bell
Affiliation:
Keywords: MRI, MRI contrast agents, Gadolinium, Cancer, Tumour, Tumour targeting, T1 contrast agents, Nanoparticles, Nanomedicine, Paramagnetic contrast agents
Abstract: For effective tumour imaging by magnetic resonance imaging (MRI) there is a clear need to develop organ, tissue and cell specific contrast agents that can selectively bind to tumour biomarkers. The versatility of a range of bioconjugation techniques and facile coupling chemistries has facilitated the synthesis of MRI contrast agents bearing tumour targeting moieties that comprise small molecule affinity ligands, peptides, antibodies and even proteins. The aim of this review is to describe the development and implementation of tumour targeted T1 MRI contrast agents, with an emphasis on the chemistry used to modify pre-existing clinical MRI contrast agents for targeted tumour imaging.
Export Options
About this article
Cite this article as:
Kamaly Nazila, D. Miller Andrew and D. Bell Jimmy, Chemistry of Tumour Targeted T1 Based MRI Contrast Agents, Current Topics in Medicinal Chemistry 2010; 10 (12) . https://dx.doi.org/10.2174/156802610791384199
DOI https://dx.doi.org/10.2174/156802610791384199 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights
Current Neuropharmacology Gankyrin Oncoprotein: Structure, Function, and Involvement in Cancer
Current Chemical Biology PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Current Medicinal Chemistry Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges
Current Pharmaceutical Biotechnology Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry Intracellular Signaling Pathways Modulated by Phenolic Compounds: Application for New Anti-Inflammatory Drugs Discovery
Current Medicinal Chemistry Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Current Molecular Pharmacology Stability Testing During Development of Nanopharmaceuticals
Pharmaceutical Nanotechnology Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors in Cancer
Current Drug Targets MicroRNAs as Potential Therapeutic Agents in the Treatment of Myocardial Infarction
Current Vascular Pharmacology Amyotrophic Lateral Sclerosis: From Research to Therapeutic Attempts and Therapeutic Perspectives
Current Medicinal Chemistry Butyrate and Colorectal Cancer: The Role of Butyrate Transport
Current Drug Metabolism Possible Binding Mode Analysis of Pyrazolo-triazole Hybrids as Potential Anticancer Agents through Validated Molecular Docking and 3D-QSAR Modeling Approaches
Letters in Drug Design & Discovery Performance of Feature Selection Methods
Current Genomics BCL-2 Family Proteins: The Mitochondrial Apoptotic Key Regulators
Current Cancer Therapy Reviews Repositioning the Old Fungicide Ciclopirox for New Medical Uses
Current Pharmaceutical Design Role of Genetic Factors in Statins Side-Effects
Cardiovascular & Hematological Disorders-Drug Targets Bioprocessing of Baculovirus Vectors: A Review
Current Gene Therapy Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism